Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.
Type 2 Diabetes Mellitus
|Study Design:||Time Perspective: Prospective|
|Official Title:||An Observational Study to Assess the Impact of Pharmacological Intervention and Life Style Changes in the Reduction of Cardiovascular Disease in Patients With Diabetes Type 2 in Greece|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00648284
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|